The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) (“Astex” or “the Company”), concerning the Company’s proposed acquisition by Otsuka Holdings Co., Ltd. (TYO: 45780) (“Otsuka”). Under the terms of the merger agreement, Astex shareholders will receive $8.50 in cash for each share of Astex common stock they own. The total transaction is valued at approximately $886 million. At least one analyst has set a target price of $13.00 for Astex shares.

The investigation is focused on the potential unfairness of the consideration to shareholders, the process by which Astex’s Board of Directors considered the transaction, and potential conflicts of interest among the Company’s Board members.

If you are interested in discussing your rights as an Astex shareholder, or have information relating to this investigation, please contact Finkelstein Thompson’s Washington, DC offices at (877) 337-1050 or by email at

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at Attorney advising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010